Loracarbef

Jump to navigation Jump to search
Loracarbef
Clinical data
Trade namesLorabid
AHFS/Drugs.comMonograph
MedlinePlusa601206
ATC code
Pharmacokinetic data
Protein binding25%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H16ClN3O4
Molar mass349.769 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Loracarbef is an antibiotic.[1] Its use was discontinued in 2006.[citation needed] It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. It was marketed under the trade name Lorabid.

Loracarbef is a synthetic "carba" analogue of cefaclor, and is more stable chemically. Diarrhea is the most common adverse effect with Loracarbef. Side effects are more frequently seen with children under the age of twelve. It received FDA approval in 1991.

Category

Carbacephem

US Brand Names

LORABID®

Mechanism of Action

Loracarbef is an oral, synthetic beta-lactam antibiotic of the carbacephem class. Loracarbef, like all beta-lactams and cephalosporins, inhibits penicillin binding proteins, enzymes that create the cross-linkage of the peptidoglycan polymer. This binding leads to interference with the formation and remodeling of the cell wall structure.

References

  1. Biedenbach DJ, Jones RN (1994). "Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef". J. Clin. Microbiol. 32 (2): 559–62. PMC 263078. PMID 8150976. Unknown parameter |month= ignored (help)

External links